[1] |
徐嵩, 赵世康, 任凡,等. 非小细胞肺癌新辅助靶向及免疫治疗研究进展和展望[J]. 中国肿瘤临床. 2020. 47: 299-303.
|
[2] |
Selvaraj G, Kaliamurthi S, Lin S, et al. Prognostic impact of tissue inhibitor of metalloproteinase-1 in non-small cell lung cancer: systematic review and meta-analysis[J]. Curr Med Chem, 2019,26:7694-7713.
|
[3] |
Hu X, Lin S, Yu D, et al. A preliminary study: the anti-proliferation effect of salidroside on different human cancer cell lines[J]. Cell Biol Toxicol, 2010,26:499-507.
|
[4] |
叶应琴, 李惠新. 红景天甙抗肿瘤作用的研究进展[J]. 临床荟萃, 2012,27:642-644.
|
[5] |
Lasorella A, Sanson M, Iavarone A. FGFR-TACC gene fusions in human glioma[J]. Neuro Oncology, 2017,19:475-483.
|
[6] |
Onodera Y, Takagi K, Miki Y,et al. TACC2 (transform-ing acidic coiled-coil protein 2) in breast carcinoma as a potent prognostic predictor associated with cell prolifera-tion[J]. Cancer Med, 2016,5:1973-1982.
|
[7] |
欧阳德亮, 刘龙飞, 王丽萍, 等. 下调TACC2表达抑制胃癌细胞增殖及上皮间充质转化[J]. 中国免疫学杂志, 2020,36:2384-2388.
|
[8] |
Hu X, Zhang X, Qiu S, et al. Salidroside induces cell-cycle arrest and apoptosis in human breast cancer cells[J]. Biochem Bioph Res Co, 2010,398:62-67.
|
[9] |
Shang H, Wang S, Yao J, et al. Salidroside inhibits migration and invasion of poorly differentiated thyroid cancer cells[J]. Thorac Cancer, 2019,10:1469-1478.
|
[10] |
Peset I, Vernos I. The TACC proteins: TACC-ling microtubule dynamics and centrosome function[J]. Trends Cell Biol, 2008,18:379-88.
|
[11] |
Cheng S, Douglas-Jones A, Yang X, et al. Transforming acidic coiled-coil-containing protein 2 (TACC2) in human breast cancer, expression pattern and clinical/prognostic relevance[J]. Cancer Genom Proteom, 2010,7:67-73.
|
[12] |
Ha GH, Park JS, Breuer EK. TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways[J]. Cancer Lett, 2013,332:63-73.
|
[13] |
彭洪, 林中超. TACC2/p300/HIF-1α信号通路对结直肠癌增殖影响的研究[J]. 实用医院临床杂志, 2018,15:17-21.
|
[14] |
Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update[J]. Arch Toxicol, 2015,89:867-882.
|